The U.S. Food and Drug Administration has approved Moderna's mFlusiva, the first flu vaccine utilizing mRNA technology similar to COVID-19 vaccines. The vaccine showed a 27% higher effectiveness rate compared to conventional flu shots in clinical trials.
